EUROIMMUN

Medizinische Labordiagnostika AG

APOE genotyping with the EURORealTime APOE

For assessment of the risk of medication side effects in anti-amyloid beta antibody therapy for Alzheimer's disease

New active substances for anti-amyloid beta antibody therapy of early-stage Alzheimer's disease (e.g. lecanemab, donanemab)

Increased risk of potentially life-threatening side effects in the form of brain swelling/bleeds (**ARIA**, amyloid-related imaging abnormalities) in carriers of two copies of the APOE allele $\varepsilon 4$



ε4/ε4 genotype is an exclusion criterion for therapy in some countries.




APOE genotyping supports the proactive evaluation of the individual ARIA risk.

Find more information on genotyping by means of PCR (polymerase chain reaction) assay on the following page.

EUROIMMUN

Medizinische Labordiagnostika AG



Regulatory status of the products must be verified for the user's individual jurisdiction. Please contact your country representative for product availability and information.

TOGETHER AT THE PULSE OF NEUROLOGY



neurodiagnostics@euroimmun.de